製藥和生物技術聯合開發交易：2016-2025

《製藥和生物技術共同開發》深入了解並分析了公司如何以及為何達成共同開發協議。

本報告提供了 2016 年至 2025 年聯合開發案的詳細資訊。提供了雙方宣布的共同開發交易的付款條款。這些數據為付款條款和其他貿易條款提供了有用的見解。

了解潛在合作夥伴談判的交易條款的靈活性可以為談判過程提供重要的見解，讓您了解在談判條款時會發生什麼。許多小型企業都希望有詳細的付款條款，但當涉及如何觸發付款和權利轉移時，細節決定成敗。

本報告提供了自 2016 年以來宣布的合作交易的綜合列表，這些交易記錄在當前協議交易和聯盟數據庫中，包括可用的財務條款，並提供了公司及其合作夥伴向 SEC 提交的實際合作交易文件的在線副本鏈接。

本報告第一章涵蓋聯合開發交易和業務活動。

第 1 章對報告進行了介紹，第 2 章概述並分析了共同開發趨勢，並討論了該交易類型的好處。

第 3 章概述了共同開發專案的結構。

第 4 章回顧了 2016 年以來具有代表性的共同開發計畫。交易按總金額列出。如果交易與美國證券交易委員會 (SEC) 發布了協議，則該連結可透過當前協議交易和聯盟資料庫在線存取該協議。

第 5 章提供了最活躍的 25 家聯合開發交易製造商的綜合清單。每個交易標題都透過我們的當前協議交易和聯盟資料庫連結到完整交易記錄的線上版本，並在可用時連結到實際合約文件，從而可以輕鬆按需存取每個交易記錄。

第 6 章全面詳細地回顧了自 2016 年以來達成或宣布的聯合開發交易，其中提供了合約文件，按公司 A-Z、治療方式、技術和行業進行組織。合約文件詳細介紹了雙方就聯合開發項目達成的實際商業條款。

交易目錄包含自 2016 年以來宣布的所有合作交易的綜合清單。每個清單都按公司 A-Z、治療領域和技術類型組織為貿易目錄。每個交易標題都透過超連結連結到交易記錄的線上版本，包括實際的合約文件（如果有）。

該報告還包含大量圖表和圖形，展示了自 2016 年以來的共同開發交易趨勢和活動。

總之，本報告提供了潛在交易者需要了解的有關聯合開發聯盟的所有資訊。

目錄

摘要整理

第1章 簡介

第2章 共同開發交易趨勢

• 簡介
• 聯合開發交易的定義
• 2016 年以來共同開發交易的趨勢
  • 2016 年至 2025 年聯合開發交易量（按年份）
  • 2016 年至 2025 年聯合開發交易（依開發階段劃分）
  • 2016 年至 2025 年聯合開發交易（按行業劃分）
  • 2016 年至 2025 年按治療領域劃分的共同開發交易
  • 2016 年至 2025 年聯合開發交易（依技術類型劃分）
  • 2016 年至 2025 年最活躍的共同開發交易（依公司劃分）
• 簽訂聯合開發協議的原因
• 聯合開發協議的未來

第3章 共同開發交易結構概要

• 簡介
• 共同開發交易結構

第4章 共同開發交易的主導

• 簡介
• 主要的共同開發交易，各金額

第5章 -最活躍的共同開發交易廠商主要25公司

• 簡介
• 最活躍的共同開發交易廠商主要25公司

包含第6章 -契約名錄的共同開發交易

• 簡介
• 按從2016年到2025年的契約共同開發交易
• 交易名錄
• 交易名錄- 各企業共同開發交易(AZ)
• 交易名錄- 共同開發交易，各治療領域
• 交易名錄- 共同開發交易，各技術類型
• 關於調查公司
• 目前聯盟
• 目前契約
• Current Partnering的最近的報告標題

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.

Fully revised and updated, the report provides details of co-development deals from 2016 to 2025.

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals.

Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.

The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.

Key benefits

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse co-development deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Co-development Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading biopharma companies worldwide.

Co-development Deals in Pharmaceuticals and Biotechnology includes:

• Trends in co-development dealmaking in the biopharma industry
• Overview of co-development deal structure
• Directory of co-development deal records covering pharmaceutical and biotechnology
• The leading co-development deals by value
• Most active co-development dealmakers
• The leading co-development partnering resources

In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Co-development Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for co-development deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking

• 2.1. Introduction
• 2.2. Definition of co-development deal
• 2.3. Trends in co-development deals since 2016
  • 2.3.1. Co-development dealmaking by year, 2016-2025
  • 2.3.2. Co-development dealmaking by phase of development, 2016-2025
  • 2.3.3. Co-development dealmaking by industry sector, 2016-2025
  • 2.3.4. Co-development dealmaking by therapy area, 2016-2025
  • 2.3.5. Co-development dealmaking by technology type, 2016-2025
  • 2.3.6. Co-development dealmaking by most active company, 2016-2025
• 2.4. Reasons for entering into co-development partnering deals
• 2.5. The future of co-development deals

Chapter 3 - Overview of co-development deal structure

• 3.1. Introduction
• 3.2. Co-development agreement structure

Chapter 4 - Leading co-development deals

• 4.1. Introduction
• 4.2. Top co-development deals by value

Chapter 5 - Top 25 most active co-development dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active co-development dealmakers

Chapter 6 - Co-development deals including contracts directory

• 6.1. Introduction
• 6.2. Co-development deals with contracts 2016-2025
• Deal directory
• Deal directory - co-development dealmaking by companies A-Z
• Deal directory - co-development dealmaking by therapy area
• Deal directory - co-development dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of co-development deal
• Figure 2: Trends in co-development deal announcements, 2016-2025
• Figure 3: Co-development deals signed at each phase of development, 2016-2025
• Figure 4: Co-development deals by industry sector, 2016-2025
• Figure 5: Co-development deals by therapy area, 2016-2025
• Figure 6: Co-development deals by technology type, 2016-2025
• Figure 7: Top 25 most active co-development dealmakers, 2016-2025
• Figure 8: Top co-development deals by value, 2016-2025
• Figure 9: Most active co-development dealmakers, 2016-2025